{
    "address": "Hyllie Boulevard 34",
    "city": "Malmo",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W1R02B107",
    "description": "Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2019-03-13",
    "isin": "SE0010573113",
    "logo": "",
    "marketCapitalization": 1201.957,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Ascelia Pharma AB",
    "phone": "46735179118.0",
    "sedol": "BH3W625",
    "shareOutstanding": 28.668262,
    "state": "SKANE",
    "ticker": "ACE.ST",
    "weburl": "http://www.ascelia.com/"
}